In the past week, GTHX stock has gone up by 2.01%, with a monthly gain of 28.81% and a quarterly surge of 53.54%. The volatility ratio for the week is 8.35%, and the volatility levels for the last 30 days are 8.79% for G1 Therapeutics Inc. The simple moving average for the past 20 days is 20.05% for GTHX’s stock, with a 85.13% simple moving average for the past 200 days.
Is It Worth Investing in G1 Therapeutics Inc (NASDAQ: GTHX) Right Now?
Company’s 36-month beta value is 1.68.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GTHX is 42.32M, and currently, short sellers hold a 6.37% ratio of that floaft. The average trading volume of GTHX on April 05, 2024 was 1.45M shares.
GTHX) stock’s latest price update
The stock of G1 Therapeutics Inc (NASDAQ: GTHX) has decreased by -3.39 when compared to last closing price of 4.72.Despite this, the company has seen a gain of 2.01% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-22 that G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company’s research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela’s net revenues in Q4 2023.
Analysts’ Opinion of GTHX
Many brokerage firms have already submitted their reports for GTHX stocks, with JP Morgan repeating the rating for GTHX by listing it as a “Neutral.” The predicted price for GTHX in the upcoming period, according to JP Morgan is $10 based on the research report published on January 30, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see GTHX reach a price target of $31, previously predicting the price at $32. The rating they have provided for GTHX stocks is “Buy” according to the report published on January 03rd, 2023.
JP Morgan gave a rating of “Underweight” to GTHX, setting the target price at $19 in the report published on November 04th of the previous year.
GTHX Trading at 26.49% from the 50-Day Moving Average
After a stumble in the market that brought GTHX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.80% of loss for the given period.
Volatility was left at 8.79%, however, over the last 30 days, the volatility rate increased by 8.35%, as shares surge +29.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.63% upper at present.
During the last 5 trading sessions, GTHX rose by +2.01%, which changed the moving average for the period of 200-days by +62.28% in comparison to the 20-day moving average, which settled at $3.85. In addition, G1 Therapeutics Inc saw 49.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GTHX starting from Umstead John W. V, who sale 6,547 shares at the price of $3.02 back on Mar 18 ’24. After this action, Umstead John W. V now owns 123,896 shares of G1 Therapeutics Inc, valued at $19,752 using the latest closing price.
Malik Rajesh, the Chief Medical Officer of G1 Therapeutics Inc, sale 28,600 shares at $4.62 during a trade that took place back on Feb 12 ’24, which means that Malik Rajesh is holding 169,938 shares at $132,143 based on the most recent closing price.
Stock Fundamentals for GTHX
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.91 for the gross margin
The net margin for G1 Therapeutics Inc stands at -0.64. The total capital return value is set at -0.43. Equity return is now at value -92.13, with -31.00 for asset returns.
Based on G1 Therapeutics Inc (GTHX), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 1.49. The interest coverage ratio of the stock is -6.81.
Currently, EBITDA for the company is -39.01 million with net debt to EBITDA at -0.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.19. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.87.
Conclusion
In a nutshell, G1 Therapeutics Inc (GTHX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
